Note: Descriptions are shown in the official language in which they were submitted.
CA 02324339 2000-09-18
- 1 -
Piperidine derivatives
The invention relates to piperidine derivatives
of the formula I
R2
1
X / Z~~N
O ~ \ ( , I R N R3
Ri
in which
X is 0, NR1, S or (CHz)n,
Y is CH,
Z is CH,
where Y and Z together can also be C=C,
R1, R2 and R3 each independently of one another are H
or A,
R4 is H, Hal, A or OA,
A is alkyl having 1-6 carbon atoms,
Hal is F, Cl, Br or I and
n is 1, 2 or 3,
and their physiologically acceptable salts.
Benzylpiperidine derivatives having a high
affinity for binding sites of amino acid receptors are
known, for example, from EP 0 709 384 Al.
The object of the invention was to discover
novel compounds having useful properties, especially
compounds which can be used for preparing medicaments.
It has been found that the compounds of the
formula I and their salts are not only well tolerated
but also have very useful pharmacological properties.
In particular, they have a very high affinity for
binding sites of amino acid receptors, especially for
the ifenprodil binding site on the NMDA receptor (NMDA
= N-methyl-D-aspartate), which modulates the polyamine
binding site allosterically.
CA 02324339 2000-09-18
- 2 -
The binding test for [3H]-ifenprodil can be conducted
by the method of Schoemaker et al., Eur. J. Pharmacol.
176, 249-250 (1990). The compounds are suitable for
treating neurodegenerative disorders, including
cerebrovascular diseases. The novel compounds can also
be used as an analgesic or anxiolytic and in the
treatment of epilepsy, schizophrenia, Alzheimer's
disease, Parkinson's disease and Huntington's disease,
cerebral ischaemias or infarcts. Furthermore, they are
suitable for treating psychoses caused by excessively
high amino acid levels.
The [3H]-CGP-39653 binding test for the
glutamate binding site of the NMDA receptor can be
conducted, for example, by the method of M.A. Stills et
al., described in Eur. J. Pharmacol. 192, 19-24 (1991).
The test for the glycine binding site of the NMDA
receptor can be conducted by the method of M.B. Baron
et al., described in Eur. J. Pharmacol. 206, 149-154
(1991).
The activity against Parkinson's disease, i.e.
the potentiation of the L-DOPA-induced contralateral
pivoting in hemiparkinsonian rats, can be detected by
the method of U. Ungerstedt and G.W. Arbuthnott, Brain
Res. 24, 485 (1970).
The compound is particularly suitable for
treatment or prophylaxis of strokes and for protection
against and treatment of cerebral oedemas and states of
undersupply of the central nervous system, especially
hypoxia or anoxia.
The activities referred to can, moreover, be
detected or checked by methods such as those described
in the following literature references:
J.W. McDonald, F.S. Silverstein and M.V. Johnston, Eur.
J. Pharmacol. 140, 359 (1987); R. Gill, A.C. Foster and
G.N. Woodruff, J. Neurosci. 7, 3343 (1987);
J.B. Bederson et al., Stroke, 17, 472-476 (1986);
S. Brint et al., J. Cereb. Blood Flow Metab. 8, 474-485
(1988).
CA 02324339 2000-09-18
- 3 -
The literature references listed below disclose
a variety of antagonists which are able to block
different binding sites of the NMDA receptor:
W. Danysz, C.G. Parsons, I. Bresink and G. Quack, Drug,
News & Perspective 8, 261 (1995), K.R. Gee, Exp. Opin.
Invest. Drugs 3, 1021 (1994) and J.J. Kulagowski and
L.L. Iversen, J. Med. Chem. 37, 4053 (1994).
Ifenprodil and eliprodil, of the formulae IIIa
and IV respectively, are able to block the NMDA
receptor by interacting with the modulatory polyamine
binding site (C.J. Carter, K.G. Lloyd, B. Zivkovic and
B. Scatton, J. Pharmacol. Exp. Ther. 253, 475 (1990)).
_ oH \ /
HO \ Q
N
_ OH \ /
CI IV
N
Since ifenprodil and eliprodil interact with
the polyamine binding site on the NMDA receptor, the
antagonistic activity of the compounds of the invention
can be determined using a spermine-stimulated [3H]-MK-
801 (dizocilpine) binding test.
In the presence of saturation concentrations of glycine
and NMDA, spermine is still able to increase the
binding of MK-801, which is inhibited by ifenprodil,
eliprodil and, very effectively, by the compounds of
the invention.
In addition, the compounds of the invention can
be tested in a[3H]-GABA (y-aminobutyric) release test,
in analogy to J. Dreijer, T. Honore and A. Schousboe,
CA 02324339 2000-09-18
- 4 -
J. Neurosci. 7, 2910 (1987), which is an in vitro model
describing the antagonistic function in the cell.
The invention provides, accordingly, the
compounds of the formula I according to Claim 1 and/or
their physiologically acceptable salts as antagonists
to receptors of excitatory amino acids, such as
glutamic acid or its salts.
The invention provides, in particular, the compounds of
the formula I according to Claim 1 and/or their
acceptable salts as excitatory amino acid antagonists
for combating neurodegenerative disorders including
cerebrovascular diseases, epilepsy, schizophrenia,
Alzheimer's disease, Parkinson's disease and
Huntington's disease, cerebral ischaemias, infarcts and
psychoses.
The invention also provides for the use of the
compounds of the formula I according to Claim 1 and/or
their physiologically acceptable salts for preparing a
medicament for combating neurodegenerative disorders
including cerebrovascular diseases, epilepsy,
schizophrenia, Alzheimer's disease, Parkinson's disease
and Huntington's disease, cerebral ischaemias, infarcts
and psychoses.
The compounds of the formula I can be employed
as an active principle of medicaments in human and
veterinary medicine.
The invention additionally provides a process
for preparing the compounds of the formula I according
to Claim 1 and their physiologically acceptable salts,
characterized in that
a) a compound of the formula II
R2
I
X / Y~Z~L
o~ I I
N ~ R3 II
Ri
CA 02324339 2000-09-18
- 5 -
in which L is Cl, Br, I, OH or a reactively
esterified OH group,
and X, Y, Z, Rl, R 2 and R3 are as defined in
Claim 1
is reacted with a compound of the formula III
HN
R4 III
in which R4 is as defined in Claim 1,
or
b) a compound of the formula I in which X, R1, R2, R3
and R4 are as defined in Claim 1, and Y and Z
together are C=C
is hydrogenated,
or
c) water or L'H is eliminated from a compound of the
formula I in which X, Rl, R3 and R4 are as defined
in Claim 1,
Y is CH,
Z is CH and
R2 is OH or L' , in which L' is Cl, Br, I, or a
reactively esterified OH group,
and/or
d) a compound of the formula I is converted by
treatment with an acid into one of its salts.
Accordingly, the invention provides in
particular those compounds of the formula I in which at
least one of the stated radicals has one of the
preferred definitions indicated above. Some preferred
groups of compounds can be expressed by the following
subformulae Ia to Ic, which correspond to the formula I
and in which those radicals not identified in any more
detail are as defined for the formula I, but in which
in Ia R1 is H;
in Ib R1 is H and
CA 02324339 2000-09-18
- 6 -
X is 0, NR1 or S;
in Ic Rl is H,
X 0, NR1 or S,
R2 is H,
R3 is H or A and
R4 is Hal.
Alkyl is preferably unbranched and has 1, 2, 3,
4, 5, 6, 7, 8, 9 or 10 carbon atoms, preferably 1, 2,
3, 4 or 5 carbon atoms, and is preferably methyl,
ethyl, trifluoromethyl, pentafluoroethyl or propyl, and
also preferably isopropyl, butyl, isobutyl, sec-butyl
or tert-butyl, but also n-pentyl, neopentyl, isopentyl
or hexyl.
The compounds of the formula I and also the
starting materials for their preparation are otherwise
prepared by methods known per se, as are described in
the literature (e.g. in the standard works such as
Houben-Weyl, Methoden der organischen Chemie, Georg-
Thieme-Verlag, Stuttgart) under reaction conditions
which are known and suitable for the stated reactions.
In this context it is also possible to make use of
variants which are known per se but are not mentioned
in any greater detail here.
If desired, the starting materials can also be
formed in situ such that they are not isolated from the
reaction mixture but instead are immediately reacted
further to give the compound of the formula I.
The compounds of the formula I can preferably
be obtained by reacting compounds of the formula II
with compounds of the formula III.
The starting compounds of the formula II are generally
novel. However, they can be prepared by methods which
are known per se.
In the compounds of the formula II, L is
preferably Cl, Br, I, OH or a reactively modified OH
group such as alkylsulfonyloxy having 1-6 carbon atoms
(preferably methylsulfonyloxy) or arylsulfonyloxy
CA 02324339 2000-09-18
- 7 -
having 6-10 carbon atoms (preferably phenyl- or p-
tolylsulfonyloxy).
The reaction of the compounds of the formula II with
compounds of the formula III generally takes place in
an inert solvent, in the presence of an acid-binding
agent, preferably an organic base such as
triethylamine, dimethylaniline, pyridine or quinoline.
It may also be advantageous to add a hydroxide,
carbonate or bicarbonate of an alkali metal or alkaline
earth metal, or another salt of a weak acid of the
alkali metals or alkaline earth metals, preferably of
potassium, sodium, calcium or caesium.
Depending on the conditions employed, the reaction time
lies between several minutes and 14 days, the reaction
temperature between about -30 and 140 , normally
between -10 and 90 and, in particular, between about
0 and about 70 .
Examples of suitable inert solvents are hydrocarbons
such as hexane, petroleum ether, benzene, toluene or
xylene; chlorinated hydrocarbons such as
trichloroethylene, 1,2-dichloroethane, carbon tetra-
chloride, chloroform or dichloromethane; alcohols such
as methanol, ethanol, isopropanol, n-propanol, n-
butanol or tert-butanol; ethers such as diethyl ether,
diisopropyl ether, tetrahydrofuran (THF) or dioxane;
glycol ethers such as ethylene glycol monomethyl or
monoethyl ether (methyl glycol or ethyl glycol),
ethylene glycol dimethyl ether (diglyme); ketones such
as acetone or butanone; amides such as acetamide,
dimethylacetamide or dimethylformamide (DMF); nitriles
such as acetonitrile; sulfoxides such as dimethyl
sulfoxide (DMSO); carbon disulfide; carboxylic acids
such as formic acid or acetic acid; nitro compounds
such as nitromethane or nitrobenzene; esters such as
ethyl acetate, water, or mixtures of the stated
solvents.
Compounds of the formula I in which Y and Z are
each CH can also be prepared, preferably, by
CA 02324339 2007-11-29
26474-488
- 8 -
hydrogenation from the compounds of the formula I in
which Y and Z together are C=C.
For this purpose it is preferred to employ
catalytic hydrogenation with, for example, palladium on
active carbon and hydrogen.
Examples of suitable catalysts for the
catalytic hydrogenation are noble metal catalysts and
nickel and cobalt catalysts. The noble metal catalysts
can be on supports (e.g. platinum or palladium on
carbon, palladium on calcium carbonate or strontium
carbonate), can be oxide catalysts (e.g. platinum
oxide), or can be finely divided metal catalysts.
Nickel catalysts and cobalt catalysts are judiciously
employed as Raney=Mmetals, nickel also on kieselguhr or
pumice as support. The hydrogenation can be conducted
at room temperature and atmospheric pressure or else at
elevated temperature and/or increased pressure. It is
preferred to operate at pressures between 1 and 100 bar
and at temperatures between -80 and +150 C, primarily
between room temperature and 100 C. The reaction is
judiciously conducted in the acidic, neutral or basic
range and in the presence of a solvent, such as water,
methanol, ethanol, isopropanol, n-butanol, ethyl
acetate, dioxane, acetic acid or THF; mixtures of these
solvents can also be employed.
Compounds of the formula I in which Y and Z
together are C=C can preferably be obtained from
compounds of the formula I in which
X, R1, R3 and R4 are as defined in Claim 1,
Y is CH,
Z is CH and
R 2 is OH or L' , in which L' is Cl, Br, I, OH or a
reactively esterified OH group,
by eliminating water or L'H from these compounds.
Elimination is preferably conducted with
aqueous acids, especially aqueous mineral acids.
L' is, for example, preferably Cl, Br, I or a
reactively modified OH group such as alkylsulfonyloxy
CA 02324339 2000-09-18
- 9 -
having 1-6 carbon atoms (preferably methylsulfonyloxy)
or arylsulfonyloxy having 6-10 carbon atoms (preferably
phenyl- or p-tolylsulfonyloxy).
The compounds in which R2 is OH or L' can be
obtained by reduction, for example, from compounds in
which Y and R2 together form a carbonyl group.
The reduction can take place as indicated by catalytic
hydrogenation, or with complex metal hydrides.
Examples of complex metal hydrides which can be
employed are NaBH4, diisobutylaluminium hydride or
NaAl(OCHzCHZOCH3)2H2 and also diborane, with the addition
if desired of catalysts such as BF3, A1C13 or LiBr.
Solvents suitable for this purpose are, in particular,
ethers, such as diethyl ether, di-n-butyl ether, THF,
dioxane, diglyme or 1,2-dimethoxyethane, and
hydrocarbons, such as benzene. For a reduction with
NaBH4, those solvents which are primarily suitable are
alcohols such as methanol or ethanol, and also water,
and aqueous alcohols. In accordance with these methods,
reduction is carried out preferably at temperatures
between -80 and +150 C, in particular between 0 and
about 100 C.
The conversion of an OH group into an OL' group
is effected by known and customary methods.
A base of the formula I can be converted into
the associated acid addition salt using an acid by
means, for example, of reacting equivalent amounts of
the base and the acid in an inert solvent such as
ethanol, followed by evaporative concentration.
Particularly suitable acids for this reaction are those
which form physiologically acceptable salts. For
instance, it is possible to use inorganic acids,
examples being sulfuric acid, nitric acid, hydrohalic
acids such as hydrochloric or hydrobromic acid,
phosphoric acids such as ortho-phosphoric acid,
sulfamic acid, and also organic acids, especially
aliphatic, alicyclic, araliphatic, aromatic or
heterocyclic mono- or polybasic carboxylic, sulfonic or
CA 02324339 2000-09-18
- 10 -
sulfuric acids, examples being formic acid, acetic
acid, propionic acid, pivalic acid, diethylacetic acid,
malonic acid, succinic acid, pimelic acid, fumaric
acid, maleic acid, lactic acid, tartaric acid, malic
acid, citric acid, gluconic acid, ascorbic acid,
nicotinic acid, isonicotinic acid, methane- or
ethanesulfonic acid, ethanedisulfonic acid, 2-
hydroxyethanesulfonic acid, benzenesulfonic acid, p-
toluenesulfonic acid, naphthalenemonosulfonic and
naphthalenedisulfonic acids, and laurylsulfuric acid.
Salts with physiologically unacceptable acids, such as
picrates, can be used to isolate and/or purify the
compounds of the formula I.
The invention additionally provides for the use
of the compounds of the formula I and/or their
physiologically acceptable salts for manufacturing
pharmaceutical preparations, especially by a non-
chemical route. In this case they can be brought into a
suitable dosage form together with at least one solid,
liquid and/or semiliquid excipient or auxiliary and, if
appropriate, in combination with one or more further
active substances.
The invention additionally provides
pharmaceutical preparations comprising an effective
amount of at least one of the compounds of the formula
I and/or one of their physiologically acceptable salts.
These preparations can be used as medicaments
in human or veterinary medicine. Suitable excipients
are organic or inorganic substances which are suitable
for enteral (e.g. oral) or parenteral administration,
topical application, or administration in the form of
an inhalation spray and which do not react with the
novel compounds, examples being water, vegetable oils,
benzyl alcohols, alkylene glycols, polyethylene
glycols, glyceryl triacetate, gelatin, carbohydrates
such as lactose or starch, magnesium stearate, talc and
vaseline. Plain tablets, pills, coated tablets,
capsules, powders, granules, syrups, juices or drops
CA 02324339 2000-09-18
- 11 -
are used in particular for oral administration,
suppositories for rectal administration, solutions,
preferably oily or aqueous solutions, and also
suspensions, emulsions or implants, for parenteral
administration, and ointments, creams or fine powders
for topical application. The novel compounds can also
be lyophilised and the resultant lyophilisates used,
for example, to manufacture preparations for injection.
The preparations indicated can be sterilized and/or may
include auxiliaries such as lubricants, preservatives,
stabilizers and/or wetting agents, emulsifiers, salts
for influencing the osmotic pressure, buffer
substances, colorants, flavourings and/or a plurality
of further active ingredients, such as one or more
vitamins.
For administration as an inhalation spray it is
possible to use sprays which comprise the active
substance either dissolved or suspended in a propellant
or mixture of propellants (e.g. COz or chloro-
fluorocarbons). In this case, the active substances are
judiciously used in micronized form with the possible
presence of one or more additional physiologically
compatible solvents, such as ethanol. Inhalation
solutions can be administered using customary inhalers.
The compounds of the formula I and their
physiologically acceptable salts can be used as
excitatory amino acid antagonists in the combating of
diseases, especially for combating neurodegenerative
disorders including cerebrovascular diseases, epilepsy,
schizophrenia, Alzheimer's disease, Parkinson's disease
and Huntington's disease, cerebral ischaemias, infarcts
and psychoses.
In these treatments, the compounds of the
invention can generally be administered in analogy to
other known compounds having a similar profile of
action, such as ifenprodil, preferably in doses of
between about 0.05 and 500 mg, in particular between
0.5 and 100 mg per dose unit. The daily dose is
CA 02324339 2007-11-29
26474-488
- 12 -
preferably between about 0.01 and 2 mg/kg of body weight.
The specific dose for each patient, however, will depend on
a wide variety of factors: for example, on the efficacy of
the specific compound employed, on the age, body weight,
general state of health, sex, diet, time and route of
administration, rate of excretion, medicament combination
and severity of the respective disorder to which the therapy
is applied. Parenteral administration is preferred.
According to another aspect of the present
invention, there is provided a compound selected from: a)
6-{3-[4-(4-fluorobenzyl)piperid-1-yl]propenyl}-3H-
benzoxazol-2-one; b) 6-{3-[4-(4-fluorobenzyl)piperid-l-
yl]propyl}-3H-benzoxazol-2-one; c) 6-{3-[4-(4-
fluorobenzyl)piperid-1-yl]propenyl}-3H-benzothiazol-2-one;
d) 5-{3-[4-(4-fluorobenzyl)piperid-1-yl]propenyl}-1,3-
dihydrobenzimidazol-2-one; or e) 5-{3-[4-(4-
fluorobenzyl)piperid-1-yl]propenyl}-1,3-dihydroindol-2-one,
or a physiologically acceptable salt thereof.
According to still another aspect of the present
invention, there is provided a commercial package comprising
a compound of the invention, or a physiologically acceptable
salt thereof, together with a written matter describing
instructions for the use thereof for combating a disease or
condition as described herein.
CA 02324339 2007-11-29
26474-488
- 12a -
Above and below, all temperatures are indicated
in C. In the examples below, "customary workup" means:
water is added if necessary, the mixture is adjusted to
a pH of between 2 and 10 if necessary, depending on the
constitution of the end product, the mixture is
extracted with ethyl acetate or dichloromethane, the
organic phase is separated off, dried. over sodium
sulfate and concentrated by evaporation, and the
residue is purified by chromatography on silica gel
andlor by crystallization.
Example 1
A suspension of . 5. 5 g of 6- ( 3-chloropropyl )-3H-
benzoxazol-2-one in 50 ml of ethanol is admixed with
5.7 g of 4-(4-fluorobenzyl)piperidine hydrochloride and
7.2 ml of triethylamine. The mixture is stirred under
reflux for one hour and subjected to customary workup
to give 8.5 g 'of 6-{3-[4-(4-fluorobenzyl)piperid-l-
yl]propyl}-3H-benzoxazol-2-one, m.p. 105-107 .
Example 2
A solution of 6.7 g of 6-f3-[4-(4-
fluorobenzyl)piperid-1-yl]-l-hydroxypropyl}-3H-benzox-
azol-2-one [obtainable by hydrogenation of 6-(3-[4-(4-
fluorobenzyl)piperid-1-yl]-1-oxopropyl)-3H-benzoxazol-
2-one, which can be obtained by reacting 4-(4-
fluorobenzyl)piperidine and 6-(3-chloropropionyl)-3H-
benzoxazol-2-one] in 70 ml of dioxane is heated under
reflux with 7 ml of concentrated HC1 for 1.5 h. The
CA 02324339 2000-09-18
- 13 -
mixture is cooled and 8.5 g of NaHCO3 and 70 ml of
water are added. 30 ml of dichloromethane are added and
the mixture is stirred for 30 minutes. The precipitate
is separated off, washed with acetone and ether and
dried to give 5.7 g of 6-{3-[4-(4-fluorobenzyl)piperid-
1-yl]propenyl}-3H-benzoxazol-2-one ("A"), M.P. 202-
203.5 ; hydrochloride: m.p. 220-223 .
The following compounds are obtained
analogously:
6-{3-[4-(4-fluorobenzyl)piperid-l-yl]-2-
methylpropenyl}-3H-benzoxazol-2-one, M.P. 156-160 ,
hydrochloride: 230-235 ;
6-{3-[4-(4-fluorobenzyl)piperid-l-yl]propenyl}-
3H-benzothiazol-2-one, hydrochloride x H20, m.p. 95-99
(decomposition);
5-{3-[4-(4-fluorobenzyl)piperid-l-yl]propenyl}-
1,3-dihydrobenzimidazol-2-one, M.P. 218-220 ;
hydrochloride: 243-245 .
5-{3-[4-(4-fluorobenzyl)piperid-l-yl]propenyl}-
1,3-dihydroindol-2-one;
6-{3-[4-(4-fluorobenzyl)piperid-1-yl]propenyl}-
3,4-dihydro-lH-quinolin-2-one.
Example 3
A solution of 2.56 g of "A" in 100 ml of
methanol and 100 ml of THF is hydrogenated at room
temperature with addition of 1.2 g of Pd/C. The
catalyst is separated off and the mixture is subjected
to customary work up to give 1.31 g of 6-{3-[4-(4-
fluorobenzyl)piperid-1-yl]propyl}-3H-benzoxazol-2-one,
m.p. 105-107 .
The following compounds are obtained
analogously, by hydrogenation:
from 6-{3-[4-(4-fluorobenzyl)piperid-1-yl]-2-
methylpropenyl}-3H-benzoxazol-2-one
6-{3-[4-(4-fluorobenzyl)piperid-l-yl]2-
methylpropyl}-3H-benzoxazol-2-one;
CA 02324339 2000-09-18
- 14 -
from 6-{3-[4-(4-fluorobenzyl)piperid-l-
yl]propenyl}-3H-benzothiazol-2-one:
6-{3-[4-(4-fluorobenzyl)piperid-1-yl]propyl}-
3H-benzothiazol-2-one;
from 5-{3-[4-(4-fluorobenzyl)piperid-l-
yl]propenylj-1,3-dihydrobenzimidazol-2-one:
5-{3-[4-(4-fluorobenzyl)piperid-l-yl]propyl}-
1,3-dihydrobenzimidazol-2-one;
from 5-{3-[4-(4-fluorobenzyl)piperid-l-
yl]propenyl}-1,3-dihydroindol-2-one:
5-{3-[4-(4-fluorobenzyl)piperid-1-yl]propyl}-
1,3-dihydroindol-2-one;
from 6-{3-[4-(4-fluorobenzyl)piperid-l-
yl]propenyl}-3,4-dihydro-lH-quinolin-2-one:
6-{3-[4-(4-fluorobenzyl)piperid-1-yl]propyl}-
3,4-dihydro-lH-quinolin-2-one.
The following examples relate to pharmaceutical
preparations:
Example A: Injection vials
A solution of 100 g of the active substance of
the formula I and 5 g of disodium hydrogen phosphate in
3 1 of double-distilled water is adjusted to a pH of
6.5 with 2 N hydrochloric acid, sterile-filtered,
transferred to injection vials, lyophilized under
sterile conditions and sterile-sealed. Each vial
contains 5 mg of active substance.
Example B: Suppositories
A mixture of 20 g of the active substance of
the formula I is melted together with 100 g of soya
lecithin and 1400 g of cocoa butter and the mixture is
poured into moulds and left to cool. Each suppository
contains 20 mg of active substance.
Example C: Solution
A solution is prepared from 1 g of the active
substance of the formula I, and 9.38 g of NaH2PO4 = 2H20,
CA 02324339 2000-09-18
- 15 -
28.48 g of NazHPO4 = 12H20 and 0.1 g of benzalkonium
chloride in 940 ml of double-distilled water. The pH is
adjusted to 6.8, and the solution is made up to 1 1 and
sterilized by irradiation. This solution can be used in
the form of eyedrops.
Example D: Ointment
500 mg of the active substance of the formula I
are mixed with 99.5 g of vaseline under aseptic
conditions.
Example E: Tablets
A mixture of 1 kg of active substance of the
formula I, 4 kg of lactose, 1.2 kg of potato starch,
0.2 kg of talc and 0.1 kg of magnesium stearate is
compressed into tablets in a customary manner such that
each tablet contains 10 mg of active substance.
Example F: Coated tablets
Tablets are pressed as in Example E and are
then coated in a customary manner with a coating of
sucrose, potato starch, talc, tragacanth and colorant.
Example G: Capsules
2 kg of active substance of the formula I are
filled into hard gelatine capsules in a customary
manner such that each capsule contains 20 mg of active
substance.
Example H: Ampoules
A solution of 1 kg of active substance of the
formula I in 60 1 of double-distilled water is sterile-
filtered, filled into ampoules and lyophilized under
sterile conditions and the ampoules are sterile-sealed.
Each ampoule contains 10 mg of active substance.
CA 02324339 2000-09-18
- 16 -
Example I: Inhalation spray
14 g of active substance of the formula I are
dissolved in 10 1 of isotonic NaCl solution and the
solution is filled into customary commercial spray
containers having a pump mechanism. The solution can be
sprayed into the mouth or nose. One burst of spray
(about 0.1 ml) corresponds to a dose of about 0.14 mg.
